Hold Rating for Qiagen Amid Horizon Europe Funding Prospects

In a report released on July 25, Aisyah Noor from Morgan Stanley maintained a Hold rating on Qiagen, with a price target of €43.00.

Aisyah Noor has given her Hold rating due to a combination of factors surrounding Qiagen’s current market position and future prospects. The announcement of the Horizon Europe framework, which proposes a significant increase in research and innovation funding, is seen as a positive development for Qiagen. The company has been involved in multiple Horizon-funded projects, leveraging its Sample Tech portfolio in various studies, which supports its growth potential.
Aisyah Noor’s rating reflects the belief that while the increased funding and Qiagen’s involvement in these projects are beneficial, the overall impact on the company’s stock may not be immediate or substantial enough to warrant a more aggressive rating. The Hold rating suggests that investors should maintain their current positions, as the long-term benefits of the Horizon Europe funding may take time to materialize fully in Qiagen’s financial performance.

In another report released on July 16, TD Cowen also maintained a Hold rating on the stock with a $49.00 price target.